|
recombinant B-domain deleted human coagulation factor VIII Fc-von Willebrand factor-XTEN fusion protein |
|---|---|
| Trade Name | |
| Orphan Indication | Hemophilia A |
| USA Market Approval | USA |
| USA Designation Date | 2017-08-03 00:00:00 |
| Sponsor | Bioverativ Therapeutics, Inc.;225 2nd Avenue;Waltham, Massachusetts, 02451 |
Related Access Program
Joanne Kurtzberg, MD – Hypoxia Ischemia, Cerebral
Genentech, Inc. – Hemophilia A
GlaxoSmithKline – Systemic Lupus Erythematosus
Vitreous -Retina- Macula Consultants of New York – Retinal Hemangioma
Xiaofan Zhu – Hematopoiesis Maintainance.
Seoul National University Hospital – Chemical Burn
Paolo Caimi, MD – Hematopoietic/Lymphoid Cancer
Zimmer Biomet – Critical Limb Ischemia
